We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Customizable AI Tool Helps Pathologists Identify Diseased Cells

By LabMedica International staff writers
Posted on 26 Jun 2024
Print article
Image: Green boxes highlight plasma cells — an indicator of infection — in a sample of the tissue lining the uterus (Photo courtesy of Zou lab and Montine lab)
Image: Green boxes highlight plasma cells — an indicator of infection — in a sample of the tissue lining the uterus (Photo courtesy of Zou lab and Montine lab)

Pathologists are tasked with examining body fluids or tissues to diagnose diseases, a process that involves distinguishing rare disease-indicating cells from thousands of normal cells under a microscope. This skill requires extensive training. Artificial intelligence (AI) can assist by learning to differentiate between healthy and diseased cells from digital pathology images. However, traditional AI tools, once trained, lack flexibility. They are designed for specific tasks, such as identifying cancer cells in one organ but not another, and might not align perfectly with a pathologist's specific needs in different scenarios. Now, a collaborative team of computer scientists and physicians has developed a new AI tool that not only identifies diseased cells but also adapts to a pathologist’s requirements.

Developed at Stanford Medicine (Stanford, CA, USA), the tool, named nuclei.io, functions like a human assistant that evolves with feedback. Starting with the basic function of recognizing different cell types by their nuclei, which house genetic material, the tool is designed to improve through interaction. Within an hour of use, nuclei.io can learn to identify the specific cells of interest to a pathologist, enhancing both the speed and accuracy of their work. During its initial trials at Stanford Medicine, the tool demonstrated its ability to speed up and enhance the diagnostic processes, reducing the time and increasing diagnostic accuracy.

In practical tests, where Stanford pathologists used the tool for tasks such as identifying immune cells in uterine biopsies for endometritis or detecting colon cancer cells in lymph nodes, nuclei.io reduced diagnostic times significantly—from 209 seconds to 79 seconds. The AI assistance made the pathologists 62% faster and 72% more accurate in their diagnoses. It is important to note that nuclei.io does not aim to replace the pathologist but rather guide them more efficiently to areas requiring detailed examination. This is part of a broader aim to ensure patients receive rapid and accurate diagnoses. Stanford Medicine pathologists are continuing to evaluate the tool’s effectiveness on a range of diseased cells, showcasing its potential to become a versatile aid in pathology.

“As we face a growing shortage of pathologists, AI tools that work in tandem with doctors have the potential to speed up some of the more tedious, time-consuming parts of our job,” said professor and chair of pathology Thomas Montine, MD, PhD. “One of the strengths of nuclei.io is that it is agnostic to application. This can be a powerful tool for interpreting any biopsy where we are trying to differentiate healthy and malignant cells. That’s not true of any other major AI tool being used in pathology right now.”

Related Links:
Stanford Medicine

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article

Channels

Clinical Chemistry

view channel
Image: The proposed self-powered, millifluidic lab-on-a-chip device to determine blood conductivity (Photo courtesy of Advanced Materials/DOI: 10.1002/adma.202403568)

First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring

Metabolic disorders such as diabetes and osteoporosis are rapidly increasing globally, especially in developing countries. Diagnosing these conditions generally requires blood tests; however, in remote... Read more

Molecular Diagnostics

view channel
Image: The U.S. FDA has granted marketing authorization for the Xpert HCV test together with the GeneXpert Xpress System (Photo courtesy of Cepheid)

First POC Hepatitis C RNA Test Enables Single-Visit Testing and Treatment

Hepatitis C, a liver infection caused by the hepatitis C virus (HCV), spreads through contact with the blood of an infected person. While some individuals may experience a short-term illness, over half... Read more

Hematology

view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.